Form DEF 14A Novavax Inc For: 27 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novavax Inc (NVAX)
The Novavax share price today is 8.070, view NASDAQ NVAX stock exchange data. Track the latest Novavax share price with real-time updates on NVAX stock performance including market cap, day range, 52-week range and dividend yield. Access NVAX charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.971
8.330
52 wk Range
5.800
11.970
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.9718.330
52 wk Range
5.80011.970
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
14.002
Upside
+73.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 13D/A NOVAVAX For: 8 April
- Investing.com
- Novavax names Robert Walker as R&D head
- Investing.com
- Form DEF 14A Novavax Inc For: 27 April
- Investing.com
- Novavax receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc Earnings Call Summary for Q4/2025
- Novavax Q4 2025 EPS of $0.11 beat forecast of -$0.49; revenue hit $147M vs. expected $90.25M, exceeding projections by 62.88%
- Full-year 2025 revenue reached $1.1B, up 65% YoY, driven by Nuvaxovid sales and partnerships with Sanofi; R&D/SG&A expenses down 42%
- Cash position strengthened to $857M at year-end 2025, bolstered by $80M in non-dilutive capital received in early 2026
- Stock rose 1.58% to $9.681 in premarket trading following earnings beat, reflecting positive investor sentiment on operational execution
- Q1 2026 guidance projects EPS of -$0.33 with $60.4M revenue; company focusing on pipeline advancement and Matrix-M adjuvant expansion
Last Updated: 26-02-2026, 09:42 pm
Read Full TranscriptCompare NVAX to Peers and Sector
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.0x | −3.3x | −0.5x | |
PEG Ratio | 0.01 | −0.17 | 0.00 | |
Price/Book | −10.3x | 2.5x | 2.6x | |
Price / LTM Sales | 1.2x | 8.7x | 3.2x | |
Upside (Analyst Target) | 98.5% | 219.8% | 47.4% | |
Fair Value Upside | Unlock | 4.9% | 6.9% | Unlock |
Analyst Ratings
5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.002
(+73.51% Upside)
Earnings
Latest Release
26-02-2026
EPS / Forecast
0.11 / -0.49
Revenue / Forecast
147M / 90.25M
FAQ
What Is the Novavax (NVAX) Share Price Today?
The Novavax share price today is 8.070.
What is the current Novavax (NVAX) share price and day range?
As of 28-04-2026, the Novavax share price is 8.070, with a previous close of 8.220. The share price has ranged from 7.971 to 8.330 today, while the 52-week range spans from 5.800 to 11.970.
What Is the Novavax Market Cap?
As of today, Novavax market cap is 1.310B.
What Is the Novavax (NVAX) Share Price Target?
The average 12-month share price target for Novavax is 14.002, with a high estimate of 25 and a low estimate of 7. 5 analysts recommend buying, while 3 suggest selling, with an overall rating of Buy and +73.51% Upside potential.
What Is Novavax's Earnings Per Share (TTM)?
The Novavax EPS (TTM) is 2.575.
When Is the Next Novavax Earnings Date?
Novavax will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is NVAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Novavax Trade On?
Novavax is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Novavax?
The stock symbol for Novavax is "NVAX."
How Many Times Has Novavax Stock Split?
Novavax has split 1 times.
How Many Employees Does Novavax Have?
Novavax has 749 employees.
What Is the NVAX Premarket Price?
NVAX's last pre-market stock price is 8.200. The pre-market share volume is 9,060.000, and the stock has changed by -0.020, or -0.240%.
What Is the NVAX After Hours Price?
NVAX's last after hours stock price is 8.130, the stock has changed by 0.060, or 0.740%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.